HALT-PKD

HALT-PKD

• 批准号: 7603689
• 负责人: ARLENE B CHAPMAN
• 金额: $ 0.83万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603689
• 关键词: Antihypertensive Agents; Autosomal Dominant Polycystic Kidney; Blood Pressure; Cessation of life; Combined Modality Therapy; Computer Retrieval of Information on Scientific Projects Database; Creatinine; End stage renal failure; Funding; Grant; Hypertension; Hypotension; Institution; Kidney; Kidney Failure; Renal function; Research; Research Personnel; Resources; Serum; Source; Standards of Weights and Measures; Time; United States National Institutes of Health; Upper arm; blood pressure regulation

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study has two arms, the aim in study A is to determine whether ADPKD subjects with preserved renal function (GFR >60 ml/min/1.73m2) and high-normal blood pressure or hypertension, ACE-I/ARB combination therapy and low blood pressure vs ¿-blocker and usual blood pressure reduces the percent increase in kidney volume over time. The aim in study B is to determine whether ADPKD subjects with moderate renal insufficiency (GFR 30-60 ml/min/1.73m2), ACE-I/ARB combination therapy as compared to ACE-I, with additional antihypertensive agents at standard blood pressure control (?130/85 mm Hg), increases the time to doubling of serum creatinine, ESRD or death.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究分为两组，研究A的目的是确定肾功能保留（GFR >60 ml/min/1.73m2）和正常高血压或高血压的ADPKD受试者，ACE-I/ARB联合治疗和低血压与受体阻滞剂和正常血压相比，是否会降低肾脏体积随时间的增加百分比。研究B的目的是确定中度肾功能不全（GFR 30-60 ml/min/1.73 m2）的ADPKD受试者，ACE-I/AR B联合治疗与ACE-I相比，在标准血压控制下是否有额外的抗高血压药物（？130/85 mm Hg），增加至血清肌酐加倍、ESRD或死亡的时间。